[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649514":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":10,"locations":10,"responsibleParty":24,"collaborators":10,"id":26,"slug":27,"hasResults":28,"nctId":29,"briefTitle":30,"officialTitle":31,"acronym":10,"eligibilityCriteria":32,"healthyVolunteers":28,"sex":33,"minAge":34,"maxAge":10,"enrollmentInfo":35,"targetDuration":38,"studyType":39,"phases":10,"briefSummary":40,"conditions":41,"keywords":43,"overallStatus":47,"whyStopped":10,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":10},{"fullName":5,"class":6},"AOP Orphan Pharmaceuticals AG","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Patients Treated With Parenteral Treprostinil",null,"Adult patients with confirmed pulmonary arterial hypertension who initiated parenteral treprostinil administered by the subcutaneous or intravenous route within 12 months of PAH diagnosis. Treatment selection, route of administration, dosing, titration, concomitant PAH therapy, and clinical management are determined by the treating physician according to routine clinical practice. Clinical, treatment, safety, and outcome data are collected retrospectively and\u002For prospectively as part of this observational registry.",[13],"Drug: treprostinil",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","treprostinil","Parenteral treprostinil administered by continuous subcutaneous or intravenous infusion as part of routine clinical care. The decision to initiate treatment, route of administration, starting dose, dose titration, treatment duration, and use of concomitant PAH therapies are determined by the treating physician and are not assigned by the registry. Data on treatment initiation, doses at approximately 2 and 4 weeks, longitudinal dosing, route of administration, tolerability, local site reactions, pain, treatment changes, and clinical outcomes are collected during registry follow-up.",[9],[21,22,23],"Parenteral Treprostinil","Subcutaneous Treprostinil","Intravenous Treprostinil",{"type":25,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100649514","treprostinil-in-pulmonary-hypertension-evidence-and-clinical-trends-100649514",false,"NCT07736846","TREPROSTINIL in Pulmonary Hypertension: Evidence and Clinical Trends","Multicenter Registry Evaluating Real-World Therapeutic Patterns and Outcomes in Newly Diagnosed Adult Patients With Pulmonary Arterial Hypertension (PAH) Treated With Parenteral Treprostinil","Inclusion Criteria:\n\n* Adult patient (≥18 years)\n* Confirmed diagnosis of PAH (i.e. Group 1 as defined by ESC\u002FERS guidelines)\n* Initiated on parenteral Treprostinil (SC or IV) anytime from 1\u002F1\u002F2024\n* Informed consent (prospective data or retrospective chart review, per local regulations)\n\nExclusion Criteria:\n\n* Participation in any interventional trials affecting PAH (including patients from TripleTRE study)\n* Non-PAH forms of pulmonary hypertension (e.g., ESC-ERS Group 2-5)","ALL","18 Years",{"count":36,"type":37},300,"ESTIMATED","36 Months","OBSERVATIONAL","TRESPECT is an international, multicenter, observational registry designed to describe the real-world use, effectiveness, and tolerability of parenteral treprostinil in adults with newly diagnosed pulmonary arterial hypertension (PAH). The registry will include patients who initiated subcutaneous or intravenous treprostinil within 12 months of PAH diagnosis.\n\nBoth retrospective and prospective data will be collected from routine clinical care. Data will include patient characteristics, PAH treatment patterns, treprostinil dosing and route of administration, functional status, exercise capacity, biomarkers, echocardiographic and hemodynamic parameters, clinical events, and adverse events. Participants will be followed for at least 36 months or until a registry termination criterion is met. The registry is expected to enroll approximately 100 to 300 patients across specialized PAH centers in several European countries.",[42],"Pulmonary Arterial Hypertension (PAH)",[44,45,21,22,46],"Pulmonary Arterial Hypertension","Treprostinil","Observational Registry","NOT_YET_RECRUITING","2026-07-26",{"date":50,"type":51},"2026-07-30","ACTUAL",{"date":53,"type":37},"2026-07",{"date":55,"type":37},"2031-12",{"name":5,"class":6}]